ライフサイエンスコーパス: participant

1 articipants) to 1% (95% CI, .2%-3%; 3 of 284 participants).

2 injection of AAV2(Y444,500,730F)-P1ND4v2 per participant.

3 itten informed consent was obtained from all participants.

4 validated in a cross-sectional cohort of 381 participants.

5 e prevalence of GSD was 5.7% of the included participants.

6 228 (6.4%) cases of incident CKD occurred in participants.

7 xpected adverse event, was documented in all participants.

8 follow-up were assessed in 28 excess-weight participants.

9 der and had more advanced disease than trial participants.

10 NA among anti-hepatitis D virus seropositive participants.

11 r more ODHs were detected in 179 eyes of 169 participants.

12 e to assess baseline DRD2 availability in 91 participants.

13 least 3 years after GT was observed for all participants.

14 le knee flexor activity was elevated in some participants.

15 d, double-blind clinical trial involving 131 participants.

16 mponent analysis ratio compared with control participants.

17 h outcomes among lower- versus higher-income participants.

18 .39-6.19) minutes more daily MVPA than other participants.

19 Only 1 participant (0.037%) was symptomatic from the CCM during

20 ppression, and we tested in 24 healthy human participants (13 females) whether the visuomotor object-

21 Of 3949 eligible participants, 16% started therapy with a statin, 11% wit

22 lation-based cohort analysis including 21870 participants (20163 free from CVD at baseline) from 3 st

23 Human participants (21 males and 28 females) underwent an init

24 LAIV H5N2 (101 participants) or placebo (51 participants) 21 days apart.

25 In an independent London-based cohort of 37 participants (23 HTT mutation carriers and 14 controls),

26 vencion con DIeta MEDiterranea) trial in 983 participants [230 cases and a random subcohort of 790 pa

27 oncentration was 26.5 (9.0) ng/mL, with 1270 participants (24.9%) being vitamin D deficient.

28 Of 30 interview participants, 25 were men (83.3%), and 21 were black (70

29 miologic links were identified in 123 of 404 participants (30%).

30 nts [230 cases and a random subcohort of 790 participants (37 overlapping cases)].Baseline concentrat

31 Of 3170 trial participants, 394 (12.4%) had BWF.

32 Of 4753 participants, 4496 (2028 men and 2468 women), with a mea

33 new diagnosis of cancer was confirmed in 109 participants, 45 (3.89%) in the vitamin D3 + calcium gro

34 A total of 251 participants (458 study eyes) were enrolled.

35 Among 480 randomized participants, 465 (97%) were included in the modified in

36 5086 participants (47 886 visits) were included in the analyt

37 Of 412 participants, 57% were women, and 57% were black; mean a

38 Among the 104 study participants (62 boys [59.6%] and 42 girls [40.4%]; mean

39 sectional, population-based random sample of participants 65 years and older was chosen from 6 study

40 Of 25 participants (71%) who completed the 24 weeks of X-82 tr

41 PrEP Participant A stopped ART and remained aviremic for 7.4

42 observed in the neuro-typical group, for ASD participants a smaller response failed to reach statisti

43 Participants' ability to adopt anticipatory strategies c

44 We scored participants according to their lifestyle factors includ

45 Participants' activity was categorized as <1000, 1000 to

46 Eligible participants aged 1-18 years with newly diagnosed cancer

47 functional brain components from 98 healthy participants aged 23-87 years from the population-based

48 lacebo-controlled, parallel-group trial, 401 participants aged 6 to 11 years were randomized to recei

49 analysed data from 2,315 cognitively healthy participants aged 65 y and over in the Cognitive Functio

50 2014 and 31 August 2015, we recruited 2,072 participants, aged 16-30 years, who were resident in the

51 However, trial participants allocated to canakinumab who achieved hsCRP

52 Human participants altered the learning rates used for the out

53 A subset of 224 eyes (123 female participants and 101 male participants; mean [SD] age, 3

54 nd histology reports were collected from all participants and evaluated by 2 independent, trained res

55 s well for puzzling behavioral data on human participants and makes predictions that could potentiall

56 We enrolled 26 participants and tested 130 seminal fluid specimens; med

57 sed, open-label, phase 3 trial that enrolled participants at 38 participating Children's Oncology Gro

58 headache, median duration <1 day) in 93% of participants at 80 ng, while AE incidence at 20 ng was s

59 tive predictive value of 98% for identifying participants at risk of further CMV reactivation.

60 The mean (SD) age of the participants at the antenatal interview was 33.20 (6.25)

61 Participants attended 1 of 22 assessment centers across

62 assessed at 90 days by postal questionnaire (participant aware, assessor blinded).

63 ded, unsupervised hierarchical clustering of participants based on global gene expression profiles re

64 from 9 European birth cohorts that enrolled participants between 1996 and 2006.

65 We recorded EEG from human participants (both genders) while they performed a modif

66 Human participants (both male and female) were instructed to s

67 , more than twice as many intervention-group participants brought up QPL-related topics during their

68 HTO) not only in typically developed control participants but also in four of the five dysplasics.

69 atory motor activity following PA in healthy participants but no effect on attention-related activity

70 We classified participants by HARSP decisions of confirmed, probable,

71 We stratified participants by quantitative QFT result (interferon-gamm

72 Participants, carers, and research assistants who collec

73 Reaction times were prolonged in SCI participants compared with control subjects and stimulat

74 group effect showing higher tracer uptake in participants compared with controls (group effect, F = 8

75 Participants completed a facial emotion and identity dis

76 Participants completed a telephone interview to determin

77 In total, 54 participants completed the study.

78 n the analytic sample (2278 HIV-seropositive participants contributed 20 477 visits and 2808 HIV-sero

79 477 visits and 2808 HIV-seronegative control participants contributed 27 409 visits).

80 Participants' CVD and CKD risk groups had multiplicative

81 Primary authors provided individual participant data from 3876 participants from 13 of 16 el

82 ing a mean follow-up of 16.6 years, 31.7% of participants developed CKD.

83 k.In 494,741 person-years of follow-up, 5207 participants developed T2DM.

84 AREDS2 participants (discovery cohort) had detailed phenotyping

85 safety results from 13 polypill trials (9059 participants) done in 32 countries.

86 es of AMT-060/kilogram was administered to 5 participants each.

87 In a multi-day fMRI study, participants encoded trial-unique associations that shar

88 HIV-infected participants enrolled in a study of cerebrospinal fluid

89 Between Dec 14, 2011, and June 24, 2014, 493 participants entered a 3 month run-in to optimise risk f

90 rolled trial, 61 healthy overweight or obese participants followed either a 5-wk very-low-calorie die

91 Among 1391 initially HCV-negative participants followed prospectively (1644.5 person-years

92 We followed participants for 35353 person-years (PY).

93 ovided individual participant data from 3876 participants from 13 of 16 eligible studies.

94 sk of cardiovascular events involving 102837 participants from 14 cohort or case-control studies cond

95 atients, 40 PD - VH patients, and 15 control participants from a prospective cohort study were includ

96 We studied participants from a randomized controlled trial of prima

97 A total of 86 participants from a TB-endemic setting, either HIV-infec

98 rum associated with prenatal iAs exposure in participants from the Biomarkers of Exposure to ARsenic

99 METHODS AND Participants from the Framingham Offspring and Third Gen

100 institutional review board approval, and all participants gave written informed consent.

101 oth including and excluding amyloid-positive participants), group differences in amyloid uptake and i

102 All participants had (13)C-spirulina GE breath test T1/2 val

103 Participants had a preintervention simulated extracorpor

104 Participants had blinded central analyses of baseline an

105 A total of 209 cognitively normal participants had data on neurodegeneration biomarkers; o

106 A total of 142 participants had follow-up data in both treatment period

107 A total of 539 participants had oral examinations in 2013.

108 A total of 13.6% of participants had PNVI, with 25.9% reporting concurrent F

109 Although HIV participants had slightly lower cognitive performance an

110 The participants identified important limitations and gaps i

111 We randomized 960 participants in 120 peer educator groups from October 18

112 lasma genitalium research agreed upon by the participants in a 2016 National Institutes of Allergy an

113 Among participants in the Clinical Phenotyping and Resource Bi

114 80 (40.0%) of 200 participants in the combination group had detectable vir

115 typhoid diagnosis was met in 24 (77%) of 31 participants in the control group, 13 (35%) of 37 partic

116 Among the participants in the genome-wide association studies, 21

117 vestigated the clinical data and sera of 722 participants in the German Multicenter Allergy Study, a

118 Compared with nonconsumers, participants in the highest quartile of coffee consumpti

119 In participants in the Jackson Heart Study, a community-bas

120 Of the 74 participants in the laboratory risky decision task (mean

121 An additional 820 EA and 57 AA participants in the Partners Biobank were genotyped and

122 No participants in the scalp cooling group received anthrac

123 Using individual-level data from 335 464 participants in the UK Biobank and summary association r

124 pants in the Vi-TT group, and 13 (35%) of 35 participants in the Vi-PS group to give vaccine efficaci

125 cipants in the control group, 13 (35%) of 37 participants in the Vi-TT group, and 13 (35%) of 35 part

126 Participants in whom a diagnosis of current asthma was u

127 The study participants included 38 nurses, 100% (n = 38) of whom w

128 Participants included term neonates with magnetic resona

129 SCORE2 enrolled 362 participants, including 305 with CRVO and 57 with HRVO.

130 P) in red blood cells was used to categorize participants into high and low drug exposure groups.

131 After 1 week, intervention participants' knowledge remained greater than controls'

132 In Experiment 1, participants made forced-choice judgments of which of tw

133 All participants maintained virological suppression (HIV-1 R

134 Among the 136 randomized participants (mean age, 50.4 [SD, 13.3] years; 42% women

135 4 eyes (123 female participants and 101 male participants; mean [SD] age, 33.0 [15.1] years) had area

136 d imputation for missing data.A total of 153 participants (means +/- SDs: BMI: 33.3 +/- 4.6; age: 63.

137 3699 (11%) of these participants met the COPD criteria and 2903 (78%) were u

138 g when it was updated annually and as cohort participants moved.

139 Human participants (N = 17) were scanned, over two sessions, w

140 ars) and an age-matched sample of comparison participants (N=18) were administered measures of cognit

141 rformance, fNIRS provided an estimate of the participants' neural efficiency, and this efficiency was

142 Based on 88 individuals among 9978 participants of 3 major Asian ethnic populations, retina

143 rify this crucial issue, we studied 87 human participants of both sexes during a stimulus-selective s

144 al associations with lifestyle factors among participants of the Danish Health Examination Survey (DA

145 adipose tissue of 770 extensively phenotyped participants of the METSIM study.

146 The intent-to-treat population included 225 participants, of whom 205 completed the study.

147 A total of 113 participants older than 50 years of age with a range of

148 oses (0.25 mL per nostril) of LAIV H5N2 (101 participants) or placebo (51 participants) 21 days apart

149 ctional connectivity in at-risk than control participants (p < .006).

150 ly restored with the implant ON in all but 1 participant (P4).

151 In 20 of 41 participants, panel genetic testing identified variants

152 Participants' performance improved with asynchronous pre

153 ensive study revealed that although most ASD participants performed atypically in at least one aspect

154 METHOD: Adult participants (persistent ADHD, N=35; remit-ted ADHD, N=4

155 The primary outcomes were participants' personal beliefs about the acceptability o

156 lant cell specialization and to reveal novel participants potentially involved in fibre metabolism re

157 measured in advance in both male and female participants, predict subsequent patterns of neural acti

158 Between 27,659 and 29,468 participants provided information on respiratory, dermal

159 Participants received half their standard TKI dose (imat

160 Participants received oral cabotegravir 30 mg tablets or

161 sula and amygdala were markedly reduced when participants received painful thermal stimuli following

162 Participants receiving insulin therapy had greater hazar

163 We show that human participants report seeing a third flash when only two a

164 Many participants reported multiple exposures to cold.

165 64%, 59%, 49%, and 18% of participants reported poor social integration, economic

166 ssion levels in whole blood samples from 150 participants, representing patients in the upper and low

167 1 [33%] of 94 participants vs 42 [49%] of 86 participants, respectively, adjusted odds ratio [aOR] 0.

168 n the interflash delay matches the period of participant's oscillatory impulse response function reve

169 We analyzed data from 7663 participants screened at least once and found to have a

170 y, as with many trials, some placebo-treated participants showed improvement on the SRS.

171 ted a stimulus set of videos, which featured participants speaking under either minimal stress, high

172 Participant-specific modeled estimates of surprise about

173 Check Hep C successfully supported high-need participants through HCV care and treatment, and SVR rat

174 ting fingerprick whole blood samples from 20 participants to assess iron status using ironPhone and c

175 me Project (PGP) is an effort to enroll many participants to create an open-access repository of geno

176 Social networks were assessed by asking participants to nominate people with whom they felt pers

177 confidence interval [CI], .1%-1.9%; 1 of 284 participants) to 1% (95% CI, .2%-3%; 3 of 284 participan

178 Finally, participants transplanted over 11 y ago showed the highe

179 Each participant underwent targeted sequencing of TGM1.

180 Participants underwent assessment during hospital admiss

181 Participants underwent CMR at baseline and after 6-month

182 Participants underwent magnetic resonance imaging and po

183 fter target appearance selectively decreased participants' updating of false prior beliefs concerning

184 tigate metacognitive abilities in compulsive participants using computational models, where these ena

185 Participants viewed a 50-min movie, then verbally descri

186 In Experiments 1 and 2, participants viewed pairs of images presented to the sam

187 up than in the control group (31 [33%] of 94 participants vs 42 [49%] of 86 participants, respectivel

188 Every participant was randomly assigned to 1 of 3 equivalent s

189 The mean (SD) age of participants was 13.2 (2.6) years; of the 115 included,

190 The mean age of participants was 69 years, 76% of participants were whit

191 the trial protocol; that of the nonenrolled participants was ad hoc.

192 The 5-year follow-up of the TWENTE participants was prespecified in the trial protocol; tha

193 Using 19,257 papers published by participants, we reconstructed their collaboration netwo

194 Participants were 18 years or older, had Diagnostic and

195 sample of 338 typically developing children, participants were 186 socioeconomically and racially/eth

196 Participants were 67% male, 84% non-Hispanic white, with

197 Eligible participants were aged 6-11 years, weighed 25 kg or more

198 Eligible participants were all women, aged 18 to 69 years, who ha

199 ion was completed by a central computer, and participants were allocated to treatment number in numer

200 Participants were asked to apply the usual diagnostic wo

201 58 (12%) of participants were classified as high-risk; the probabili

202 lly evaluable population, 199 (77.4%) of 257 participants were clinically cured in the ceftazidime-av

203 Participants were community-dwelling men (44.2%) and wom

204 Participants were drawn from two different localities in

205 1680 participants were enrolled and randomly allocated betwee

206 1800 participants were enrolled between Dec 5, 2014, and Feb

207 In 3 experiments participants were exposed to a standard CC procedure dur

208 In an initial learning phase participants were exposed to a subset of auditory-visual

209 Of these, 553 participants were female (61.0%) and 550 were African-Am

210 A total of 80,285 AHSMOG-2 participants were followed for an average of 7.5 years w

211 Participants were followed from 1985 to 2009, and the me

212 py twice daily for 5 days, given orally, and participants were followed up for 28 days.

213 Subsequently, participants were followed up until January 1, 2015, for

214 All participants were followed-up for medically certified ca

215 During Visit 1, 356 (39.3%) participants were graded with a normal image.

216 Potential participants were identified as having sustained minor i

217 All participants were in the Mayo Clinic Study of Aging, a p

218 l editors (n = 9), and regulators (n = 2) (3 participants were included in 2 groups each), culminatin

219 seven trials with 363 dental implants in 262 participants were included in the analysis.

220 baseline, mean age was 55 years old, 37% of participants were men, and mean eGFR was 94 ml/min per 1

221 We excluded studies if more than 20% of participants were military, if they were of deminers, if

222 Participants were monitored in an outpatient setting wit

223 Participants were not masked to treatment, but the adjud

224 Participants were randomised to active (n=12) versus sha

225 Participants were randomized to one of the following stu

226 Participants were randomly assigned to 2 groups: 1 using

227 Participants were randomly assigned to daily subcutaneou

228 Participants were randomly assigned to iCST (75, 30-min

229 Participants were recruited from the osteoarthritis outp

230 Between Nov 11, 2015, and July 15, 2016, 742 participants were screened for eligibility, of whom 657

231 Participants were stratified based on the body mass inde

232 Eight thousand five hundred eighty-one study participants were surveyed in 3 sites.

233 All participants were tested with binocular infrared video g

234 ean age of participants was 69 years, 76% of participants were white, and 90% were non-Hispanic.

235 Median age was 36 years, 48% of participants were women, and 77% were enrolled at the U.

236 Twenty-one studies (13982 participants) were included.

237 -free net reclassification improvement among participants who experienced an ASCVD event (0.390; 95%

238 Of the 1667 participants who fulfilled the inclusion criteria, all c

239 The analysis included only participants who had suicidal ideation at baseline (N=16

240 the subset of 8590 UK Biobank Imaging study participants who had undergone depression assessments.

241 Participants who received antivascular endothelial growt

242 The LMCI participants who received IVIG performed better on Alzhe

243 By week 12, 62 (17%) of participants who received rifampicin versus 71 (18%) who

244 Among the 238 participants who started ART within 6 months of enrolmen

245 Of 14496 participants who underwent LITA+SVG, 2803 (19%) were wom

246 We therefore selected participants who varied along this dimension and applied

247 Participants who were aged at least 18 years with influe

248 ch academic transplant centers and involving participants who were at least 16 years old, had undergo

249 Moreover, participants who were in the higher cholesterol efflux/a

250 ent early menopause were identified from all participants who were premenopausal at baseline in 1991;

251 ife was saved by the donation) increased the participants' willingness to commit to organ donation th

252 e events in the bevacizumab group included 1 participant with endophthalmitis (culture negative), 9 w

253 d with BCVA of less than 20/40 compared with participants with 20/40 or better (HR, 1.56; 95% CI, 1.0

254 The sample contained 1 738 886 participants with a mean age of 55.6 years (SD 9.7), 59.

255 adermal, but not intramuscular, vaccination, participants with AD with S aureus colonization experien

256 tes against influenza H1N1 than noncolonized participants with AD.

257 d Eye Disease Study 2 Ancillary SD OCT study participants with age-related macular degeneration (AMD)

258 ytes were measured in sputum samples from 48 participants with asthma.

259 Fifty-one of 1452 participants with baseline CD4 count <350 cells/muL deve

260 (2009-2013) relative to baseline among those participants with baseline eGFR >/=60 ml/min per 1.73 m(

261 Similar results were seen for participants with baseline vitamin D deficiency and for

262 A total of 16 participants with BSI from 13 kindreds were identified f

263 uation of early-onset myocardial infarction, participants with CHIP had a risk of myocardial infarcti

264 A total of 237 (15%) of the adult participants with chronic HBV infection that were enroll

265 for the treatment of acute HCV infection in participants with chronic human immunodeficiency virus t

266 perception in a cohort (n=161) comprising 36 participants with CKD, 100 participants with ESRD, and 2

267 The proportions of participants with culture-positive PTB initiated on appr

268 61) comprising 36 participants with CKD, 100 participants with ESRD, and 25 controls.

269 We followed up participants with HIV from the Veterans Aging Cohort Stu

270 e events in the aflibercept group included 4 participants with intraocular pressure (IOP) more than 1

271 sed study on subclinical atherosclerosis, 40 participants with IPH at baseline magnetic resonance (MR

272 open-label, blinded-endpoint trial in adult participants with ischaemic stroke or transient ischaemi

273 ectional, and case-control studies including participants with joint inflammation and no previous def

274 Fifty eyes of 50 participants with keratoconus.

275 Participants with known hypertension in communities that

276 The primary endpoint was the proportion of participants with less than 50 copies per mL of plasma H

277 tive to those with high salivary FGF2, human participants with low salivary FGF2 exhibited significan

278 nd, randomized, placebo-controlled study, 74 participants with peanut allergy (ages 4-25 years) were

279 , 75%-97%; kappa = 0.88) in a subgroup of 37 participants with photographs considered of high enough

280 Participants with pre-existing CVD were excluded from th

281 inistration of tuberculosis (TB) vaccines in participants with previous or current pulmonary TB may h

282 Participants with PTSD (n = 28) showed more eye-blink re

283 s 7.3% for diabetes in 572 observations from participants with SCT and 6877 observations from partici

284 was statistically significantly lower among participants with SCT when defined using HbA1c values (2

285 1 to 3 mg/L and 1.12 (95% CI, 0.65-1.93) for participants with serum CRP >3 mg/L.

286 ng estimate was 0.97 (95% CI, 0.57-1.66) for participants with serum CRP levels of 1 to 3 mg/L and 1.

287 lobal gene expression profiles revealed that participants with significantly higher serum vitamin D3

288 Participants with T2DM exhibited greater heterogeneity o

289 The C statistic for discriminating between participants with versus without any masked hypertension

290 coagulant activity was sustained in all the participants, with a mean (+/-SD) steady-state factor IX

291 vs 32%; p=0.0279) than did pregnant control participants, with comparable severe hypoglycaemia episo

292 version was 100% in Vi-TT and 88.6% in Vi-PS participants, with significantly higher geometric mean t

293 One participant withdrew from the trial 240 days after enrol

294 staff blinded to group randomization, and no participants withdrew because of an adverse event.

295 Two participants withdrew from the AQ-13 group after parasit

296 37 years) was used as a cutoff to categorize participants within the FIT interval cancer category.

297 w diabetes cases were recorded among 482,591 participants without prevalent (previously diagnosed or

298 riate p = .007) compared with trauma-exposed participants without PTSD (n = 26).

299 icipants with SCT and 6877 observations from participants without SCT; P<.001 for both comparisons).

300 ilk and fat content.A total of 103,256 adult participants (women: 51.0%) from Northern Sweden were in